Emergent BioSolutions receives high marks from European Commission

The European Commission recently published its sixth European Union Survey on Research and Development Investment Business Trends, ranking Emergent BioSolutions, Inc., high on its list.

The survey included a list of the research and development investment expectations of the top 1,000 EU and non-EU companies. Emergent BioSolutions, Inc., the makers of the only U.S. Food and Drug Administration approved vaccine for the treatment of anthrax, made the cut, according to

Emergent BioSolutions, Inc., was ranked at  number 41 in the biotechnology sector of the top 1,000 non-EU companies that invest the most in research and development. In the United States, the Rockville-based company was ranked number 399 in the company list. Out of all the non-EU companies examined, Emergent BioSolutions, Inc., was ranked at number 823.

According to the survey, the top research and development companies in the EU expect investments to grow five percent each year between 2011 and 2013. Five percent is double what was expected last year and is a significant improvement from 2009, when research and development investments were cut by 2.6 percent.

“The survey provides welcome positive economic news and grounds for cautious medium-term optimism, given that business R&D is a key driver of sustainable growth and jobs,” Maire Geoghegan-Quinn, the EU commissioner for research, innovation and science, said, reports.